←Back to list

Lark

Developer of virtual chronic disease prevention and management platform designed to manage and prevent chronic condition
Developer of virtual chronic disease prevention and management platform designed to manage and prevent chronic conditions of patients.
Business/Productivity Software 📍 Singapore, Singapore Founded 2016
Current Valuation
$816.3M
as of 2024-Q3
PRIVATE

QL Price

$4.1B
-32% vs last round
QuantLogix's current estimate for Lark, published 2026-09-27 — below the last disclosed round of $6.0B (2026-05).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round $6.0B 2026-05 weight 0.75
Secondary market print $1.6B 2026-06-27 weight 0.58
How this price has held up
No round has priced for Lark since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
How to actually get exposure to Lark →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Lark, 2026-09-27 (28d68faa8d9822e7). The id pins this exact claim, so a citation stays checkable after the price moves. Model estimate for research — not a quote, target price, or investment advice.

IPO Outlookprivate

Is Lark going public?
No. Lark is private and has not filed to go public. There is no S-1 on file.
What is Lark's valuation in 2026?
Lark is valued at $816.3M as of 2024-Q3, set by its Series D ($16.3M, Sep 2024). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Lark filed an S-1?
No public S-1 is on file for Lark.
How much has Lark raised?
Lark has raised $226.05M in total, most recently a Series D of $16.3M in Sep 2024.
Is Lark publicly traded — can you buy Lark stock?
No. Lark is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Lark on its Pre-IPO Access Desk.
How to actually get exposure to Lark →
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.

Company Profile

Founded
2016
HQ
Singapore, Singapore
Total Raised
$226.05M
Last Round
Series D — $16.3M (Sep 2024)
IPO Status
private

Fundraising Status

Series D · $16.3M · 2y ago
privateTotal raised $226.05M

Secondary Market

Implied price / share
$4
Last round price / share
$15.42
vs last round
-74.1%
Last round price vs secondary price
Last round vs current secondary price per share$15.42Last round$4.00Current
Secondary price return by period
Secondary market period returns3-month0.0%6-month-34.0%1-year-43.6%All-time-74.1%
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →

Latest Funding Round

RoundAmountDateLead InvestorPost-Money
Series D$16.3MSep 2024—$816.3M

Talent Signal

Hiring trend
▼ Hiring downtrend
-50% vs 2026-08
Open roles
1
via ashby
Product-build share
0%
engineering, research, product, design
Trajectory
tightening
go-to-market push — Only 0% of open roles build product — hiring is concentrated in sales/marketing/ops (1 of 1 open roles are operations).
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by month2Aug '261Sep '26
Open roles by function
Open roles by functionOps & People1
■ product-building   ■ go-to-market / G&A
Clinical Operations Lead
Counted from Lark's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
SoftwareHealth CareArtificial IntelligenceWellnessMedical Device
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q3. Refreshed quarterly.